Alternative Name
IDH1 R132H
Methodology
Immunohistochemistry (IHC)
Test Description
IDH1 mutations are frequent genetic alterations in low-grade diffuse gliomas and secondary glioblastoma (70%). This alteration is observed in fewer than 10% of primary GBM cases. IDH1 IHC antibody is a diagnostic tool in assessing the IDH1 R132H mutational status and differentiating primary GBM tumors from the others.
Specimen Requirements
- A formalin-fixed, paraffin-embedded (FFPE) tissue block is preferred specimen type
or - One (1) unbaked, unstained slide for H&E staining (required) and two to three (2-3) positively charged unstained slides (all cut at 4-5 microns) for each test/antibody ordered
- Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Storage & Transportation
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.
CPT Code(s)*
88342 x 1 or 88341 x 1
Turnaround Time
Tech-Only (stain only): 24 hours
Level of Service
Stain Only
New York Approved
Yes
Notes
Global prognostic interpretation is available (TAT is 48 hours)